The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
|Articles|September 7, 2021
Pfizer Starts Phase 3 Trial for RSV Vaccine
Author(s)John Parkinson
The first participants were vaccinated in the study with Pfizer’s respiratory syncytial virus (RSV) investigational vaccine candidate in adults ages 60 or older.
Advertisement
Pfizer recently announced it had begun its phase 3 clinical trial, RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease), which was designed to evaluate the efficacy, immunogenicity, and safety of a single dose of its RSV bivalent prefusion F subunit investigational vaccine candidate, RSVpreF.
The vaccine is being studied in a global, randomized, double-blind, placebo-controlled study that expects to enroll approximately 30,000 adults 60 years and older. The study will assess safety and efficacy for the prevention of moderate to severe lower respiratory tract illness (msLRTI-RSV) during the first RSV season.
“RSV is a significant cause of severe respiratory disease in older adults, and it can cause disability and death. There is an important unmet medical need for an effective vaccine that can help protect older adults against this highly-contagious disease,” Kathrin U. Jansen, PhD, senior vice president and head of Vaccine Research & Development, Pfizer, said. “The start of this phase 3 study is an important step forward towards our goal of comprehensive immunization against RSV disease, which includes developing a potential first vaccine to help prevent RSV disease in adults as well as the ongoing efforts to help protect infants through maternal immunization, subject to regulatory approval of the candidate vaccine.”
The Centers for Disease Control and Prevention (CDC) states that an estimated 177,000 older adults are hospitalized and 14,000 of them die in the United States annually due to RSV.
Those older adults who are most at risk for severe RSV are those who are 65 years and older; adults who have chronic heart or lung disease; and adults with weakened immune systems. RSV in adults will look like cold symptoms, but can lead to more serious symptoms including pneumonia, severe symptoms for people with asthma, chronic obstructive pulmonary disease, and congestive heart failure.
For providers, the CDC has a page with more clinical information, which can be accessed
Advertisement
Related to this article
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.